1. Home
  2. ABLV vs NSPR Comparison

ABLV vs NSPR Comparison

Compare ABLV & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

N/A

Current Price

$2.16

Market Cap

44.9M

Sector

N/A

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

N/A

Current Price

$0.62

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABLV
NSPR
Founded
2015
2005
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
38.9M
IPO Year
2022
2009

Fundamental Metrics

Financial Performance
Metric
ABLV
NSPR
Price
$2.16
$0.62
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
★ 159.5K
45.1K
Earning Date
04-27-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,310,000.00
Revenue This Year
N/A
$9.14
Revenue Next Year
N/A
$105.44
P/E Ratio
$16.70
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.54
$0.60
52 Week High
$2.00
$2.57

Technical Indicators

Market Signals
Indicator
ABLV
NSPR
Relative Strength Index (RSI) N/A 30.55
Support Level N/A $0.63
Resistance Level N/A $0.72
Average True Range (ATR) 0.00 0.06
MACD 0.00 -0.01
Stochastic Oscillator 0.00 30.83

Price Performance

Historical Comparison
ABLV
NSPR

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: